Gianluca Sala

List of Publications by Year
in descending order

66 papers	1,915 citations	257450 24 h-index	265206 42 g-index
69 all docs	69 docs citations	69 times ranked	2819 citing authors

#	Article	IF	Citations
1	Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer. Gut, 2023, 72, 360-371.	12.1	8
2	BAG3 induces fibroblasts to release key cytokines involved in pancreatic cell migration. Journal of Cellular Biochemistry, 2022, 123, 65-76.	2.6	6
3	Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans. Cell Death and Disease, 2022, 13, 274.	6.3	11
4	Concerted BAG3 and SIRPα blockade impairs pancreatic tumor growth. Cell Death Discovery, 2022, 8, 94.	4.7	2
5	Breast cancer in the era of integrating "Omics" approaches. Oncogenesis, 2022, 11, 17.	4.9	23
6	High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors. Journal of Experimental and Clinical Cancer Research, 2021, 40, 63.	8.6	13
7	USP19 modulates cancer cell migration and invasion and acts as a novel prognostic marker in patients with early breast cancer. Oncogenesis, 2021, 10, 28.	4.9	13
8	EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors. Pharmaceutics, 2021, 13, 483.	4.5	7
9	Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review. Cancers, 2021, 13, 3126.	3.7	12
10	Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target. Journal of Translational Medicine, 2021, 19, 405.	4.4	50
11	MYC regulates metabolism through vesicular transfer of glycolytic kinases. Open Biology, 2021, 11, 210276.	3.6	5
12	Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma. Cancers, 2020, 12, 2989.	3.7	16
13	Antibody-Drug Conjugates: The New Frontier of Chemotherapy. International Journal of Molecular Sciences, 2020, 21, 5510.	4.1	83
14	Engineered Human Nanoferritin Bearing the Drug Genz-644282 for Cancer Therapy. Pharmaceutics, 2020, 12, 992.	4.5	12
15	HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies. EMBO Molecular Medicine, 2020, 12, e11498.	6.9	30
16	Repurposing a psychoactive drug for children with cancer: p27Kip1-dependent inhibition of metastatic neuroblastomas by Prozac. Oncogenesis, 2020, 9, 3.	4.9	5
17	EV20-sss-vc/MMAF, an HER-3 targeting antibody-drug conjugate displays antitumor activity in liver cancer. Oncology Reports, 2020, 45, 776-785.	2.6	3
18	Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 312.	8.6	18

#	Article	IF	Citations
19	PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes. BMC Cancer, 2019, 19, 747.	2.6	22
20	Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation. Cancers, 2019, 11, 1695.	3.7	4
21	Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 191.	8.6	14
22	ABCC3 is a novel target for the treatment of pancreatic cancer. Advances in Biological Regulation, 2019, 73, 100634.	2.3	18
23	miRâ€574â€5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGESâ€1 induction. FASEB Journal, 2019, 33, 6933-6947.	0.5	30
24	Development of an antiâ€BAG3 humanized antibody for treatment of pancreatic cancer. Molecular Oncology, 2019, 13, 1388-1399.	4.6	18
25	Secreted Gal-3BP is a novel promising target for non-internalizing Antibodyâ€"Drug Conjugates. Journal of Controlled Release, 2019, 294, 176-184.	9.9	30
26	CAF-Derived IL6 and GM-CSF Cooperate to Induce M2-like TAMsâ€"Letter. Clinical Cancer Research, 2019, 25, 892-893.	7.0	10
27	Abstract 238: Therapeutic activity of the non-internalizing antibody drug conjugate 1959-sss/DM3 targeting galectin3-binding protein in human neuroblastoma. , 2019, , .		1
28	Abstract 238: Therapeutic activity of the non-internalizing antibody drug conjugate 1959-sss/DM3 targeting galectin3-binding protein in human neuroblastoma. , 2019, , .		0
29	Combined effect of anti-BAG3 and anti-PD-1 treatment on macrophage infiltrate, CD8+ T cell number and tumour growth in pancreatic cancer. Gut, 2018, 67, gutjnl-2017-314225.	12.1	33
30	EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma. Journal of Controlled Release, 2018, 277, 48-56.	9.9	23
31	Role of BAG3 in cancer progression: A therapeutic opportunity. Seminars in Cell and Developmental Biology, 2018, 78, 85-92.	5.0	61
32	GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Oncogene, 2018, 37, 6368-6382.	5.9	77
33	Abstract 748: Non-internalizing site-specific antibody-drug conjugates based on maytansinoids display curative properties. , 2018, , .		1
34	Abstract 741: Targeting trastuzumab and T-DM-1 resistant breast cancer cells with EV20/MMAF, an antibody drug-conjugate against HER3. , 2018, , .		0
35	The role of phospholipase CÎ³1 in breast cancer and its clinical significance. Future Oncology, 2017, 13, 1991-1997.	2.4	11
36	Functional and prognostic significance of the genomic amplification of frizzled 6 (*FZD6*) in breast cancer. Journal of Pathology, 2017, 241, 350-361.	4.5	66

#	ARTICLE	IF	CITATIONS
37	Therapeutic Efficacy of the Novel Stimuli-Sensitive Nano-Ferritins Containing Doxorubicin in a Head and Neck Cancer Model. International Journal of Molecular Sciences, 2017, 18, 1555.	4.1	33
38	Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma. Oncotarget, 2017, 8, 60368-60377.	1.8	13
39	EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma. Oncotarget, 2017, 8, 95412-95424.	1.8	22
40	Abstract 40: Development of a novel antibody-drug conjugate targeting endosialin/TEM-1: potent antitumor activity in sarcoma. , 2017, , .		0
41	Abstract 41: An Antibody Drug Conjugate targeting HER-3 demonstrates promising antitumor efficacy in a wide range of human cancer. , 2017, , .		0
42	p63 role in breast cancer. Aging, 2016, 8, 2256-2257.	3.1	10
43	miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance. Cell Death and Disease, 2015, 6, e1823-e1823.	6.3	74
44	BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. Nature Communications, 2015, 6, 8695.	12.8	81
45	HER-3: hub for escape mechanisms. Aging, 2015, 7, 899-900.	3.1	4
46	Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget, 2015, 6, 3932-3946.	1.8	60
47	ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs). Oncotarget, 2015, 6, 16902-16911.	1.8	29
48	Abstract LB-A14: Targeting BAG3-dependent paracrine loop reduces growth and metastatic spreading of Pancreatic adenocarcinoma. , 2015, , .		0
49	Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. Oncogenesis, 2014, 3, e117-e117.	4.9	13
50	505 The anti-ErbB3 antibody, EV20, counteracts vemurafenib resistance in BRAF-mutated colorectal cancer stem cells. European Journal of Cancer, 2014, 50, 164-165.	2.8	0
51	Abstract 5437: Dual targeting of ErbB-2 and ErbB-3: A new potential strategy for the treatment of pancreatic cancer. , 2014, , .		0
52	EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. Translational Oncology, 2013, 6, 676-IN9.	3.7	26
53	An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. Oncogene, 2012, 31, 1275-1286.	5.9	28
54	1226 POSTER An ErbB-3 Antibody, MP-RM-1, Inhibits Tumour Growth by Blocking Ligand-dependent and Independent Activation of ErbB-3/Akt Signaling. European Journal of Cancer, 2011, 47, S152.	2.8	0

#	Article	IF	Citations
55	Effects of an ErbB-3 antibody, MP-RM-1, on tumor growth and ligand-dependent and -independent activation of ErbB-3/akt signaling.. Journal of Clinical Oncology, 2011, 29, e13538-e13538.	1.6	0
56	Abstract C58: Humanization and characterization of an anti-ErbB-3 murine monoclonal antibody.. , 2011, , .		0
57	A Phosphoinositide 3-Kinase/Phospholipase Cgamma1 Pathway Regulates Fibroblast Growth Factor-Induced Capillary Tube Formation. PLoS ONE, 2009, 4, e8285.	2.5	37
58	Phospholipase CÎ³1 Is Required for Metastasis Development and Progression. Cancer Research, 2008, 68, 10187-10196.	0.9	135
59	The Role of Phosphoinositide 3-Kinase C2Î± in Insulin Signaling. Journal of Biological Chemistry, 2007, 282, 28226-28236.	3.4	136
60	Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene, 2005, 24, 4540-4548.	5.9	111
61	Feedback inhibition by RALT controls signal output by the ErbB network. Oncogene, 2003, 22, 4221-4234.	5.9	112
62	Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control. Oncogene, 2002, 21, 6530-6539.	5.9	73
63	Negative regulation of receptor tyrosine kinase signals. FEBS Letters, 2001, 490, 132-141.	2.8	32
64	The E27 Î²2-adrenergic Receptor Polymorphism Reduces the Risk of Myocardial Infarction in Dyslipidemic Young Males. Thrombosis and Haemostasis, 2001, 85, 231-233.	3.4	13
65	The E27 beta2-adrenergic receptor polymorphism reduces the risk of myocardial infarction in dyslipidemic young males. Thrombosis and Haemostasis, 2001, 85, 231-3.	3.4	6
66	The Gâ€‘proteinâ€‘coupled receptor kinase GRK4 mediates homologous desensitization of metabotropic glutamate receptor 1. FASEB Journal, 2000, 14, 2569-2580.	0.5	131